Resources

As we engage as an Association in the development of the life science sector plan, the 10 year NHS plan and the UK’s industrial strategy this winter, this week I’ve been reflecting on what recent NHS announcements on adoption of innovation tell us.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

The potential presented by Engineering Biology (EngBio), both globally and for the UK, is difficult to overstate. Realisation of this potential across sectors as diverse as health, energy, materials, chemicals production and waste management, will be achieved by providing the right tools to help companies of all sizes as they innovate and translate those innovations to commercial scale.

In this guest blog, Luis Lacerda and Suzanne Farid from UCL explore the transformative potential of engineering biology and its critical role in addressing sustainability challenges in medicines manufacturing.

A new industry briefing note developed by Pioneer Group in collaboration with the UK chemicals sector community highlights the urgent need for the sector to transition to a more sustainable, circular economy.

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18.

Ingenza welcomes Lisa Fraser as she takes on the role of Senior Project Manager, effective immediately.

GitLife Biotech Ltd. has appointed Beatrix Ellis as its new CEO. With extensive experience in commercial strategy and business development, this appointment marks a pivotal moment for GitLife.

Read the latest antibody industry report which report which aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September). Besides PiaSky, Vyloy, Imdelltra, Tribuvia, and ivonescimab, five more novel antibody drugs have been approved this year.

In this blog, Izzy Webb outlines why the UK has published voluntary guidance to promote DNA synthesis and who the guidance is intended for.

The Milner Therapeutics Institute has joined a three-year collaboration with the science funding agency ARIA and multiple Cambridge partners.

The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.

Financing led by Ahren, OMX Ventures and Paladin Capital Group represents one of the largest UK biotech Series A rounds in recent years.

Recent research indicates that the rate of global warming caused by human activity is at an all-time high. In response, Pioneer Group, a specialist in life science infrastructure and venture building, is ramping up its support for start-up businesses tackling planetary health challenges.

Newcells Biotech (“Newcells”) today announced the launch of its proprietary CiliaBeat software and application in a Lung Ciliary Beat Frequency Analysis assay.

A great opportunity to learn about the challenges of space travel and how our drugs can help!

ERS Genomics Limited (ERS), the CRISPR licensing Company, and Medicines Discovery Catapult (MDC), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology.